Sanofi SA
SNY
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
E: investor.relations@sanofi.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Sanofi SA News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
Can you achieve global diversification with multinational companies?
A Morningstar report explores if the benefits of global investing can be achieved by investing in global companies trading on local exchanges.
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.70 | 18.10 | 0.20% |
| CAC 40 | 7,825.24 | 1.72 | 0.02% |
| DAX 40 | 23,698.15 | 5.50 | -0.02% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.29 | 14.29 | -0.15% |
| HKSE | 26,388.16 | 301.84 | 1.16% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,227.90 | 1.25 | -0.01% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,864.90 | 22.00 | 0.25% |
| SSE Composite Index | 3,870.60 | 4.71 | -0.12% |